Select a Size
| Size/SKU | Availability | Price |
|---|---|---|
5 mg | Available to ship TODAYfromMILWAUKEE | $282.00 |
10 mg | Available to ship TODAYfromMILWAUKEE | $516.00 |
25 mg | Estimated to ship onNovember 30, 2026fromMILWAUKEE | $1,120.00 |
About This Item
$282.00
Available to ship TODAYDetails
Product Name
3,4-Dichloroisocoumarin, serine protease inhibitor
Quality Segment
assay
≥98% (TLC)
form
powder
solubility
ethyl acetate: 49.00-51.00 mg/mL, clear, colorless to faintly yellow
storage temp.
2-8°C
SMILES string
ClC1=C(Cl)c2ccccc2C(=O)O1
InChI
1S/C9H4Cl2O2/c10-7-5-3-1-2-4-6(5)9(12)13-8(7)11/h1-4H
InChI key
SUGXUUGGLDCZKB-UHFFFAOYSA-N
General description
Application
Preparation Note
Other Notes
1 of 1
This Item | |||
|---|---|---|---|
| description serine protease inhibitor | description - | description 99% | description ≥99%, FCC, FG |
| assay ≥98% (TLC) | assay ≥99% (elemental analysis) | assay 99% | assay ≥99% |
| Quality Level 200 | Quality Level 100 | Quality Level 100 | Quality Level 400, 300 |
| form powder | form lyophilized solid | form liquid | form - |
| solubility ethyl acetate: 49.00-51.00 mg/mL, clear, colorless to faintly yellow | solubility DMSO: 10 mM, DMF: 10 mM | solubility - | solubility - |
| storage temp. 2-8°C | storage temp. 2-8°C | storage temp. - | storage temp. - |
Still not finding the right product?
Explore all of our products under 3,4-Dichloroisocoumarin
Signal Word
Danger
Hazard Codes
Precautionary Statements
Hazard Classifications
Acute Tox. 3 Oral - Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3
Target Organs
Respiratory system
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
PPE (personal protective equipment)
Eyeshields, Faceshields, Gloves, type P2 (EN 143) respirator cartridges
Choose from one of the most recent versions:
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.



